The company sources raw materials to support its commercial, clinical, and preclinical operations, ensuring that third-party suppliers comply with regulatory and internal quality standards. Supplier selection is based on qualifications, expertise, capacity, location, reputation, and reliability. The company maintains a diversified global supply network that includes internal manufacturing and global contract manufacturers, supported by safety stock strategies to prevent supply disruptions. It holds commercial supply agreements with manufacturing service providers and an ex-China API source approved by the FDA and EMA in 2025. For in-licensed products from Amgen and others, supply depends on the licensors and their manufacturing facilities or contract manufacturing organizations (CMOs). Agreements with outsourced suppliers address quality, technical standards, delivery, pricing, and inspection criteria, while suppliers procure raw materials independently. Raw materials include active pharmaceutical ingredients (APIs) custom-made by third-party CMOs, excipients from established vendors, and genetically modified cell lines co-developed and licensed from Boehringer Ingelheim and others. Orders are generally placed on a purchase order basis without long-term capacity commitments, and suppliers are typically not liable for defects in finished products.
Beone Medicines Ltd's Comment on Supply Chain
The company sources raw materials to support its commercial, clinical, and preclinical operations, ensuring that third-party suppliers comply with regulatory and internal quality standards. Supplier selection is based on qualifications, expertise, capacity, location, reputation, and reliability. The company maintains a diversified global supply network that includes internal manufacturing and global contract manufacturers, supported by safety stock strategies to prevent supply disruptions. It holds commercial supply agreements with manufacturing service providers and an ex-China API source approved by the FDA and EMA in 2025. For in-licensed products from Amgen and others, supply depends on the licensors and their manufacturing facilities or contract manufacturing organizations (CMOs). Agreements with outsourced suppliers address quality, technical standards, delivery, pricing, and inspection criteria, while suppliers procure raw materials independently. Raw materials include active pharmaceutical ingredients (APIs) custom-made by third-party CMOs, excipients from established vendors, and genetically modified cell lines co-developed and licensed from Boehringer Ingelheim and others. Orders are generally placed on a purchase order basis without long-term capacity commitments, and suppliers are typically not liable for defects in finished products.
Sources:
Beone Medicines Ltd 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Beone Medicines Ltd ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
